US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US7063967B2
(en)
|
1997-05-08 |
2006-06-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US7541020B2
(en)
*
|
1997-05-08 |
2009-06-02 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6764840B2
(en)
|
1997-05-08 |
2004-07-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
AU773921B2
(en)
*
|
1997-05-08 |
2004-06-10 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
TR200103266T2
(tr)
*
|
1999-05-13 |
2002-01-21 |
American Cyanamid Company |
Yardımcı kombinasyon formülasyonları
|
AU779978B2
(en)
*
|
1999-10-07 |
2005-02-24 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
KR100919916B1
(ko)
|
2000-02-23 |
2009-10-07 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
종양 특이적 동물 단백질
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6699846B2
(en)
*
|
2000-03-17 |
2004-03-02 |
Corixa Corporation |
Mono- and disaccharides for the treatment of nitric oxide related disorders
|
CA2396762A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
|
PL206832B1
(pl)
|
2000-05-19 |
2010-09-30 |
Corixa Corp |
Zastosowanie związków opartych na mono- i disacharydach
|
US20030105032A1
(en)
*
|
2000-05-19 |
2003-06-05 |
Persing David H. |
Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
|
US20030139356A1
(en)
*
|
2001-05-18 |
2003-07-24 |
Persing David H. |
Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
US7129219B2
(en)
|
2000-08-04 |
2006-10-31 |
Corixa Corporation |
Immunoeffector compounds
|
EA004744B1
(ru)
*
|
2000-11-10 |
2004-08-26 |
Уайт Холдингз Корпорейшн |
Комбинированные композиции адъювантов
|
JP2008531580A
(ja)
*
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾因子の標的化送達のための組成物および方法
|
DK1355918T5
(da)
|
2000-12-28 |
2012-02-20 |
Wyeth Llc |
Rekombinant beskyttelsesprotein af streptococcus pneumoniae
|
US20040236072A1
(en)
*
|
2001-04-13 |
2004-11-25 |
Olmsted Stephen Bruce |
Surface proteins of streptococcus pyogenes
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
CA2444133A1
(en)
|
2001-04-16 |
2002-10-24 |
Wyeth Holdings Corporation |
Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
EP1515982A4
(de)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
US6911434B2
(en)
*
|
2002-02-04 |
2005-06-28 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
|
KR100858947B1
(ko)
*
|
2002-02-04 |
2008-09-17 |
코릭사 코포레이션 |
면역효과기 화합물을 사용하는 감염성 질환 및 기타질환의 예방학적 및 치료학적 처치
|
JP2005516980A
(ja)
*
|
2002-02-04 |
2005-06-09 |
コリクサ コーポレイション |
新規な免疫エフェクター化合物
|
US7030094B2
(en)
*
|
2002-02-04 |
2006-04-18 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
|
US20030190333A1
(en)
*
|
2002-02-04 |
2003-10-09 |
Corixa Corporation |
Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
|
US7026465B2
(en)
*
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
US7351413B2
(en)
*
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
EP1478327B1
(de)
*
|
2002-02-22 |
2015-04-29 |
Meda AB |
Verfahren zur reduzierung und behandlung von uvb-induzierter immunsuppression
|
WO2003073827A2
(en)
*
|
2002-02-28 |
2003-09-12 |
Corixa Corporation |
Methods of modulating dendritic cells using adjuvants
|
KR100981471B1
(ko)
*
|
2002-03-15 |
2010-09-10 |
더 큐레이터스 오브 더 유니버시티 오브 미주리 |
효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의p4 변형 단백질
|
JP5014573B2
(ja)
*
|
2002-05-09 |
2012-08-29 |
オンコサイレオン インコーポレーテッド |
脂質aおよび他の炭水化物リガンド類似体
|
IL166178A0
(en)
*
|
2002-07-08 |
2006-01-15 |
Corixa Corp |
Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor
|
US7288640B2
(en)
*
|
2002-07-08 |
2007-10-30 |
Corixa Corporation |
Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
ZA200505302B
(en)
*
|
2003-01-06 |
2007-03-28 |
Corixa Corp |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
*
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7375180B2
(en)
*
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
EP1599726A4
(de)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
Selektive modulation von tlr-vermittelter biologischer aktivität
|
EP1601365A4
(de)
|
2003-03-04 |
2009-11-11 |
3M Innovative Properties Co |
Prophylaktische behandlung von uv-induzierter epidermaler neoplasie
|
JP2006520245A
(ja)
|
2003-03-13 |
2006-09-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
入れ墨の除去方法
|
US8426457B2
(en)
*
|
2003-03-13 |
2013-04-23 |
Medicis Pharmaceutical Corporation |
Methods of improving skin quality
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US7923560B2
(en)
*
|
2003-04-10 |
2011-04-12 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
CN1852711A
(zh)
*
|
2003-08-05 |
2006-10-25 |
3M创新有限公司 |
使用免疫响应调节化合物的传染病预防
|
BRPI0412902A
(pt)
|
2003-08-12 |
2006-09-26 |
3M Innovative Properties Co |
compostos contendo imidazo substituìdo por oxima
|
JP2007504145A
(ja)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性の組み合わせおよび治療
|
CA2536136C
(en)
|
2003-08-27 |
2012-10-30 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
AU2004270201A1
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
CA2540541C
(en)
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
US20050096259A1
(en)
*
|
2003-10-31 |
2005-05-05 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
US8598192B2
(en)
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
WO2005048933A2
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
AU2004293078B2
(en)
|
2003-11-25 |
2012-01-19 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
JP2007513165A
(ja)
*
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物を含む併用薬および治療方法
|
EP2460813A1
(de)
|
2003-12-17 |
2012-06-06 |
Janssen Alzheimer Immunotherapy |
Beta-Immunogen-Peptidträgerkonjugate und Herstellungsverfahren dafür
|
JP4764830B2
(ja)
|
2003-12-17 |
2011-09-07 |
ワイス・エルエルシー |
免疫原性ペプチド担体コンジュゲートおよびその生産法
|
EP1701955A1
(de)
|
2003-12-29 |
2006-09-20 |
3M Innovative Properties Company |
Arylalkenyl- und arylalkinylsubstituierte imidazochinoline
|
WO2005066169A2
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
EP1699398A4
(de)
*
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
Verbesserung der immunantworten
|
CA2559863A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
MXPA06012451A
(es)
*
|
2004-04-28 |
2007-01-31 |
3M Innovative Properties Co |
Composiciones y metodos para vacunacion por la mucosa.
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
EP2301957A3
(de)
|
2004-05-21 |
2011-05-18 |
Wyeth LLC |
Modifiziertes Fibronectin-bindendes Protein von Stapylococcus aureus
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
WO2005123080A2
(en)
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
JP2008515928A
(ja)
*
|
2004-10-08 |
2008-05-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
Dnaワクチンのためのアジュバント
|
AU2005333603A1
(en)
|
2004-10-21 |
2007-01-04 |
Wyeth |
Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
|
US7943609B2
(en)
|
2004-12-30 |
2011-05-17 |
3M Innovative Proprerties Company |
Chiral fused [1,2]imidazo[4,5-C] ring compounds
|
ES2392648T3
(es)
|
2004-12-30 |
2012-12-12 |
3M Innovative Properties Company |
Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
|
CA2594253C
(en)
|
2004-12-30 |
2015-08-11 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
US9248127B2
(en)
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
EP1846405A2
(de)
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Oxim- und hydroxylaminsubstituierte imidazo-4,5-c-ringverbindungen und verfahren
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
AU2006232377A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
CN102716480B
(zh)
|
2005-04-08 |
2023-03-21 |
惠氏有限责任公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物
|
US20080193474A1
(en)
*
|
2005-04-25 |
2008-08-14 |
Griesgraber George W |
Immunostimulatory Compositions
|
US20080213318A1
(en)
*
|
2005-07-05 |
2008-09-04 |
Hawaii Biotech, Inc. |
Malaria MSP-1 C-terminal enhanced subunit vaccine
|
CN101378778B
(zh)
|
2005-12-22 |
2013-02-06 |
葛兰素史密丝克莱恩生物有限公司 |
肺炎球菌多糖缀合物疫苗
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1988896A4
(de)
*
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
Konjugate zur modifizierung von immunreaktionen
|
EP2476433A1
(de)
|
2006-03-30 |
2012-07-18 |
GlaxoSmithKline Biologicals S.A. |
Immunogene Zusammensetzung
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
EP2390363A1
(de)
|
2006-06-02 |
2011-11-30 |
GlaxoSmithKline Biologicals s.a. |
Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen PRF1
|
WO2008008432A2
(en)
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
NZ574239A
(en)
|
2006-07-18 |
2011-12-22 |
Glaxosmithkline Biolog Sa |
Hybrid fusion proteins for malaria vaccines
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
EP2086582B1
(de)
|
2006-10-12 |
2012-11-14 |
GlaxoSmithKline Biologicals s.a. |
Impfstoff mit einem öl-in-wasser-emulsionshilfsstoff
|
US20090285819A1
(en)
*
|
2006-11-15 |
2009-11-19 |
Functional Genetics, Inc. |
Methods and compositions for treating influenza
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
SI2137210T1
(sl)
|
2007-03-02 |
2017-01-31 |
Glaxosmithkline Biologicals S.A. |
Nov postopek in sestavki
|
MX351247B
(es)
*
|
2007-04-04 |
2017-10-05 |
Infectious Disease Res Institute Star |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AU2008267208B2
(en)
|
2007-06-26 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
PL2173376T3
(pl)
|
2007-08-02 |
2015-08-31 |
Biondvax Pharmaceuticals Ltd |
Multimeryczne wieloepitopowe szczepionki przeciwko grypie
|
EP2201131B8
(de)
|
2007-09-17 |
2014-12-10 |
MDxHealth SA |
Verbesserter methylierungsnachweis
|
US20090215710A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Carbohydrate based toll-like receptor (tlr) antagonists
|
AU2008352942B2
(en)
|
2007-12-19 |
2013-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
PE20091104A1
(es)
*
|
2007-12-21 |
2009-07-18 |
Wyeth Corp |
Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo
|
SI2222710T1
(sl)
|
2007-12-24 |
2016-11-30 |
Id Biomedical Corporation Of Quebec |
Rekombinatni RSV antigeni
|
BRPI0911195A2
(pt)
|
2008-04-09 |
2017-06-20 |
The Univ Of North Caroline At Chapel Hill |
métodos de regulação de arranjo de citoesqueleto de actina e formação de gap intracelular
|
RS54306B1
(en)
|
2008-04-16 |
2016-02-29 |
Glaxosmithkline Biologicals S.A. |
THE VACCINE
|
CN102316894A
(zh)
|
2008-06-20 |
2012-01-11 |
惠氏有限责任公司 |
来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
|
NZ614064A
(en)
*
|
2008-11-05 |
2015-04-24 |
Wyeth Llc |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
|
EP2356225A1
(de)
|
2008-12-03 |
2011-08-17 |
Protea Vaccine Technologies Ltd. |
Glutamyl-trna-synthetase-(gts-)fragmente
|
CA2748038A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Glaxosmithkline Biologicals S.A. |
Method for inducing a trif-bias
|
WO2010079081A1
(en)
|
2009-01-07 |
2010-07-15 |
Glaxosmithkline Biologicals S.A. |
Methods for recovering a virus or a viral antigen produced by cell culture
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
EP2393922A1
(de)
|
2009-02-06 |
2011-12-14 |
GlaxoSmithKline Biologicals S.A. |
Aufreinigung von virus oder viralen antigenen mittels dichtegradienten-ultrazentrifugation
|
WO2010094663A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxosmithkline Biologicals S.A. |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
MX2011009597A
(es)
|
2009-03-17 |
2012-05-29 |
Glaxosmithkline Biolog Sa |
Deteccion mejorada de la expresion del gen.
|
AU2010233151A1
(en)
*
|
2009-04-09 |
2011-11-17 |
The University Of North Carolina At Chapel Hill |
Methods of treating edema related to ischemia-reperfusion
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
US9125951B2
(en)
|
2009-06-22 |
2015-09-08 |
Wyeth Llc |
Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
|
SI2445522T1
(sl)
|
2009-06-22 |
2017-10-30 |
Wyeth Llc |
Imunogeni sestavki antigenov Staphylococcusa aureusa
|
CA2766211A1
(en)
|
2009-06-24 |
2010-12-29 |
Glaxosmithkline Biologicals S.A. |
Recombinant rsv antigens
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
CA2767392C
(en)
|
2009-07-06 |
2017-03-14 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
EP3988115A3
(de)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
WO2011036220A1
(en)
|
2009-09-25 |
2011-03-31 |
Glaxosmithkline Biologicals S.A. |
Immunodiffusion assay for influenza virus
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
ES2562818T3
(es)
|
2010-05-03 |
2016-03-08 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de inactivación del virus de la gripe
|
GB201009273D0
(en)
|
2010-06-03 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel vaccine
|
SI3170508T1
(sl)
|
2010-06-04 |
2020-01-31 |
Wyeth Llc |
Formulacije cepiva
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
HRP20210242T4
(hr)
|
2010-08-23 |
2024-05-10 |
Wyeth Llc |
Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
|
CN103096920B
(zh)
|
2010-09-10 |
2016-03-23 |
惠氏有限责任公司 |
脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
US9352030B2
(en)
|
2010-12-14 |
2016-05-31 |
Glaxosmithkline Biologicals, S.A. |
Mycobacterium antigenic composition
|
CA2819120C
(en)
|
2010-12-22 |
2016-07-05 |
Wyeth Llc |
Stable immunogenic compositions of staphylococcus aureus antigens
|
WO2012097346A1
(en)
|
2011-01-13 |
2012-07-19 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating viral infections
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
US8889616B2
(en)
|
2011-02-24 |
2014-11-18 |
Oncothyreon Inc. |
MUC1 based glycolipopeptide vaccine with adjuvant
|
WO2012156391A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
AU2012261959B2
(en)
|
2011-06-03 |
2015-12-03 |
Solventum Intellectual Properties Company |
Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
|
CN103582496B
(zh)
|
2011-06-03 |
2016-05-11 |
3M创新有限公司 |
具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
GB201119999D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201120000D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2802353A4
(de)
|
2012-01-12 |
2015-12-02 |
Variation Biotechnologies Inc |
Zusammensetzungen und verfahren zur behandlung von virusinfektionen
|
US20150079077A1
(en)
|
2012-01-27 |
2015-03-19 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
BR122016004924A2
(pt)
|
2012-03-09 |
2019-07-30 |
Pfizer Inc. |
Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
|
WO2013139744A1
(en)
|
2012-03-18 |
2013-09-26 |
Glaxosmithkline Biologicals S.A. |
Method of vaccination against human papillomavirus
|
WO2013150518A1
(en)
|
2012-04-01 |
2013-10-10 |
Rappaport Family Institute For Research In The Medical Sciences |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
CN104854128A
(zh)
|
2012-07-19 |
2015-08-19 |
硕腾有限责任公司 |
牛流感病毒组合物
|
AU2013295770A1
(en)
|
2012-07-27 |
2015-01-29 |
Zoetis Services Llc |
Tick toxin compositions
|
JP2015525794A
(ja)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
MX363511B
(es)
|
2012-08-16 |
2019-03-26 |
Pfizer |
Proceso de glucoconjugación y composiciones.
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
HRP20221438T1
(hr)
|
2012-12-20 |
2023-02-03 |
Pfizer Inc. |
Postupak glikokonjugiranja
|
EP2762152A1
(de)
|
2013-02-05 |
2014-08-06 |
Nitto Denko Corporation |
WT1-Peptidkrebsimpfstoffzusammensetzung zur transdermalen Verabreichung
|
JP2014169280A
(ja)
|
2013-02-05 |
2014-09-18 |
Nitto Denko Corp |
経皮または粘膜投与用ワクチン組成物
|
CN103961700A
(zh)
|
2013-02-05 |
2014-08-06 |
日东电工株式会社 |
粘膜给予用疫苗组合物
|
US20140234377A1
(en)
|
2013-02-05 |
2014-08-21 |
Nitto Denko Corporation |
Vaccine composition for mucosal administration
|
US10076491B2
(en)
|
2013-02-05 |
2018-09-18 |
Nitto Denko Corporation |
Vaccine composition
|
EP2762154A3
(de)
|
2013-02-05 |
2015-01-21 |
Nitto Denko Corporation |
Impfstoff zur transdermalen Verabreichung
|
CA2840988A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Wt1 peptide cancer vaccine composition for mucosal administration
|
IN2014CH00391A
(de)
|
2013-02-05 |
2015-04-03 |
Nitto Denko Corp |
|
IN2014CH00393A
(de)
|
2013-02-05 |
2015-04-03 |
Nitto Denko Corp |
|
CN103961696A
(zh)
|
2013-02-05 |
2014-08-06 |
日东电工株式会社 |
经皮给予用疫苗组合物
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
AU2014234982A1
(en)
|
2013-03-15 |
2015-09-24 |
Zoetis Services Llc |
Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine
|
EP3608332B1
(de)
|
2013-03-15 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Impfstoff gegen humanes rhinovirus
|
ES2743465T3
(es)
|
2013-03-15 |
2020-02-19 |
Glaxosmithkline Biologicals Sa |
Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
BE1022008B1
(fr)
|
2013-08-05 |
2016-02-03 |
Glaxosmithkline Biologicals S.A. |
Compositions immunogenes combinees
|
ES2778928T3
(es)
|
2013-08-30 |
2020-08-12 |
Glaxosmithkline Biologicals Sa |
Producción a gran escala de virus en cultivos celulares
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP2015059577A
(ja)
|
2013-09-17 |
2015-03-30 |
Ntn株式会社 |
チェーン伝動装置
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
JP6612260B2
(ja)
|
2014-01-21 |
2019-11-27 |
ファイザー・インク |
肺炎連鎖球菌(Streptococcus pneumoniae)莢膜多糖およびそのコンジュゲート
|
SI3096786T1
(sl)
|
2014-01-21 |
2021-09-30 |
Pfizer Inc. |
Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
|
WO2016130569A1
(en)
|
2015-02-09 |
2016-08-18 |
Mj Biologics, Inc. |
A composition comprising pedv antigens and methods for making and using the composition
|
US10668164B2
(en)
|
2014-02-14 |
2020-06-02 |
Pfizer Inc. |
Immunogenic glycoprotein conjugates
|
EP3556353A3
(de)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipidnanopartikel-impfstoffadjuvanzien und antigenfreisetzungssysteme
|
ES2702325T3
(es)
|
2014-03-11 |
2019-02-28 |
Univ Minnesota |
Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
|
EP3116480A1
(de)
|
2014-03-12 |
2017-01-18 |
GlaxoSmithKline Biologicals S.A. |
Immunogene liposomale formulierung
|
WO2015136479A1
(en)
|
2014-03-12 |
2015-09-17 |
Glaxosmithkline Biologicals S.A. |
Liposomal compositions for mucosal delivery
|
CN106163553B
(zh)
|
2014-04-03 |
2021-07-23 |
彼昂德瓦克斯医药有限公司 |
多聚体-多表位流感多肽的组合物及其产生
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
AR101256A1
(es)
|
2014-07-21 |
2016-12-07 |
Sanofi Pasteur |
Composición vacunal que comprende ipv y ciclodextrinas
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
JP2018509384A
(ja)
|
2015-01-06 |
2018-04-05 |
イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. |
リピドa模倣体、調製方法、及びその使用
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
AU2016221318B2
(en)
|
2015-02-19 |
2020-06-25 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
NZ734998A
(en)
|
2015-03-12 |
2024-01-26 |
Zoetis Services Llc |
Pyolysin methods and compositions
|
EP3292146A1
(de)
|
2015-05-04 |
2018-03-14 |
Pfizer Inc |
Gruppe-b-streptococcus-polysaccharid-proteinkonjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
|
WO2016191553A1
(en)
|
2015-05-26 |
2016-12-01 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
WO2017021792A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Biologicals Sa |
Tlr4 agonists and compositions thereof and their use in the treatment of cancer
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
WO2017030901A1
(en)
|
2015-08-14 |
2017-02-23 |
Zoetis Services Llc |
Mycoplasma bovis compositions
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
US10772946B2
(en)
|
2015-10-13 |
2020-09-15 |
Sanofi Pasteur |
Immunogenic compositions against S. aureus
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
NZ738202A
(en)
|
2015-12-03 |
2019-07-26 |
Glaxosmithkline Ip Dev Ltd |
Cyclic purine dinucleotides as modulators of sting
|
WO2017097783A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Biologicals S.A. |
Novel adjuvant formulations
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
CA3010977A1
(en)
|
2016-01-11 |
2017-07-20 |
Zoetis Services Llc |
Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
|
WO2017137085A1
(en)
|
2016-02-11 |
2017-08-17 |
Sanofi Pasteur |
Meningitidis vaccines comprising subtilinases
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
JP6746712B2
(ja)
|
2016-04-07 |
2020-08-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
タンパク質調節因子として有用な複素環式アミド
|
SG11201808708RA
(en)
|
2016-04-07 |
2018-11-29 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
CR20180521A
(es)
|
2016-05-05 |
2019-01-15 |
Glaxosmithkline Ip No 2 Ltd |
Inhibidores del potenciador del homólogo zeste 2
|
WO2017210215A1
(en)
|
2016-05-31 |
2017-12-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Army |
Zika virus vaccine and methods of production
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(de)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
|
WO2018015879A1
(en)
|
2016-07-20 |
2018-01-25 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
EP3504230A1
(de)
|
2016-08-23 |
2019-07-03 |
GlaxoSmithKline Biologicals SA |
Fusionspeptide mit an kurze fragmente einer invarianten kette (cd74) gebundenen antigenen
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
US20190365710A1
(en)
|
2016-12-01 |
2019-12-05 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
CA3045952A1
(en)
|
2016-12-07 |
2018-06-14 |
Glaxosmithkline Biologicals Sa |
Novel process
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
CN110225757A
(zh)
|
2017-01-31 |
2019-09-10 |
默沙东公司 |
由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
WO2018183666A1
(en)
|
2017-03-31 |
2018-10-04 |
Boston Medical Center Corporation |
Methods and compositions using highly converved pneumococcal surface proteins
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
US20210187098A1
(en)
|
2017-04-28 |
2021-06-24 |
Glaxosmithkline Biologicals Sa |
Vaccination
|
US11389465B2
(en)
|
2017-05-01 |
2022-07-19 |
Vanderbilt University |
Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
GB2600652B
(en)
|
2017-05-30 |
2022-11-02 |
Glaxosmithkline Biologicals Sa |
Novel compositions
|
TW201925222A
(zh)
|
2017-06-23 |
2019-07-01 |
美商醫院疫苗公司 |
免疫原性組成物
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
CN118063638A
(zh)
|
2017-09-07 |
2024-05-24 |
默沙东有限责任公司 |
肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
CA3075207A1
(en)
|
2017-09-13 |
2019-03-21 |
Sanofi Pasteur |
Human cytomegalovirus immunogenic composition
|
CN111417630B
(zh)
|
2017-10-05 |
2023-06-06 |
葛兰素史克知识产权开发有限公司 |
干扰素基因刺激因子(sting)的调节剂
|
EP3692033A1
(de)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulatoren des stimulators von interferongenen (sting) zur verwendung bei der behandlung von hiv
|
JP7197880B2
(ja)
*
|
2017-10-19 |
2022-12-28 |
学校法人 名城大学 |
エステル化剤及びその利用
|
JP7369123B2
(ja)
|
2017-12-06 |
2023-10-25 |
メルク・シャープ・アンド・ドーム・エルエルシー |
肺炎球菌多糖類-タンパク質コンジュゲートを含む組成物およびその使用方法
|
MX2020008417A
(es)
|
2018-02-12 |
2020-11-11 |
Inimmune Corp |
Ligandos de receptores de tipo toll.
|
CA3091352A1
(en)
|
2018-02-21 |
2019-08-29 |
The University Of Montana |
Diaryl trehalose compounds and uses thereof
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Il−15バリアントおよびその使用
|
WO2019169313A1
(en)
|
2018-03-02 |
2019-09-06 |
The University Of Montana |
Immunogenic trehalose compounds and uses thereof
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
TWI803637B
(zh)
|
2018-05-23 |
2023-06-01 |
美商輝瑞大藥廠 |
特異性針對gucy2c之抗體及其用途
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
EP3574915A1
(de)
|
2018-05-29 |
2019-12-04 |
Neovacs |
Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität
|
BR112020024285A2
(pt)
|
2018-06-12 |
2021-03-02 |
Glaxosmithkline Biologicals S.A. |
polinucleotídeos e polipeptídeos de adenovírus
|
EP3581201A1
(de)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 polypeptide und verwendungen davon
|
BR112020027090A2
(pt)
|
2018-07-31 |
2021-03-30 |
Glaxosmithkline Biologicals S.A. |
Método de purificação de antígenos
|
WO2020031087A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
EP3851120A4
(de)
|
2018-09-11 |
2022-04-27 |
Shanghai Public Health Clinical Center |
Immunogen für influenza-impfstoff mit breitem spektrum und anwendung davon
|
WO2020109365A1
(en)
|
2018-11-29 |
2020-06-04 |
Glaxosmithkline Biologicals Sa |
Methods for manufacturing an adjuvant
|
MA54533A
(fr)
|
2018-12-19 |
2022-03-30 |
Merck Sharp & Dohme |
Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
SG11202112870WA
(en)
|
2019-05-23 |
2021-12-30 |
The Univ Of Montana |
Vaccine adjuvants based on tlr receptor ligands
|
AU2020308053A1
(en)
|
2019-06-26 |
2022-01-20 |
Glaxosmithkline Intellectual Property Development Limited |
IL1RAP binding proteins
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
EP3999093A4
(de)
|
2019-07-19 |
2023-11-22 |
Merck Sharp & Dohme LLC |
Antigene glykoprotein-e-polypeptide, zusammensetzungen und verfahren zu deren verwendung
|
EP3999108A1
(de)
|
2019-07-21 |
2022-05-25 |
GlaxoSmithKline Biologicals S.A. |
Therapeutischer viraler impfstoff
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
AU2020323498A1
(en)
|
2019-07-31 |
2022-03-03 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
BR112022004228A2
(pt)
|
2019-09-09 |
2022-05-31 |
Glaxosmithkline Biologicals Sa |
Composições imunoterapêuticas
|
AU2020355614A1
(en)
|
2019-09-27 |
2022-04-14 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
EP4061412A1
(de)
|
2019-11-22 |
2022-09-28 |
GlaxoSmithKline Biologicals S.A. |
Dosierung und verabreichung eines bakteriellen saccharid-glykokonjugat-impfstoffes
|
WO2021124073A1
(en)
|
2019-12-17 |
2021-06-24 |
Pfizer Inc. |
Antibodies specific for cd47, pd-l1, and uses thereof
|
AU2021218797A1
(en)
|
2020-02-13 |
2022-08-25 |
The Board Of Trustees Of The University Of Illinois |
Vaccine and methods for detecting and preventing filariasis
|
JP2023522050A
(ja)
|
2020-04-16 |
2023-05-26 |
パーイミューン エスエーエス |
血管炎の処置のための住血吸虫由来の28kda gstタンパク質
|
US20230146256A1
(en)
|
2020-04-17 |
2023-05-11 |
Regents Of The University Of Minnesota |
SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
|
EP3900739A1
(de)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
|
EP4146378A1
(de)
|
2020-05-05 |
2023-03-15 |
GlaxoSmithKline Biologicals S.A. |
Mikrofluidische mischvorrichtung und verfahren zur verwendung
|
MX2022015287A
(es)
|
2020-06-01 |
2023-02-22 |
Loop Diagnostics S L |
Metodo y kit para la deteccion temprana de septicemia.
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
MX2022016181A
(es)
|
2020-06-22 |
2023-02-13 |
Sumitomo Pharma Co Ltd |
Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4).
|
TW202216779A
(zh)
|
2020-07-17 |
2022-05-01 |
美商輝瑞股份有限公司 |
治療性抗體類和彼等之用途
|
CA3192786A1
(en)
|
2020-08-26 |
2022-03-03 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
JP2023542141A
(ja)
|
2020-09-15 |
2023-10-05 |
ザ ユニバーシティー オブ モンタナ |
繊維状バクテリオファージを標的化する組成物および方法
|
IL301402A
(en)
|
2020-09-17 |
2023-05-01 |
Inst Nat Sante Rech Med |
An immunogenic product containing a segment of ige for the treatment of inflammatory disorders mediated by ige
|
EP4245763A1
(de)
|
2020-11-11 |
2023-09-20 |
Daiichi Sankyo Company, Limited |
Neues aminoalkylglucosaminid-4-phosphatderivat
|
IL303334A
(en)
|
2020-12-02 |
2023-07-01 |
Glaxosmithkline Biologicals Sa |
The perfect fimh by a donor strand
|
EP4032547A1
(de)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce abgeleitete fragemente zur hsv therapie
|
US20240115674A1
(en)
|
2021-02-03 |
2024-04-11 |
The Board Of Trustees Of The University Of Illinois |
Vaccine and methods for preventing filariasis and dirofilariasis
|
MX2023009456A
(es)
|
2021-02-11 |
2023-08-28 |
Glaxosmithkline Biologicals Sa |
Preparacion de la vacuna contra el vph.
|
AU2022230795A1
(en)
|
2021-03-02 |
2023-09-21 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
EP4314060A1
(de)
|
2021-03-31 |
2024-02-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigenbindende proteine und kombinationen davon
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
CN114318353B
(zh)
*
|
2021-12-27 |
2023-12-05 |
广东红日星实业有限公司 |
一种除灰剂及其制备方法和应用
|
WO2024069420A2
(en)
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Immunogenic compositions comprising an rsv f protein trimer
|